The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs).
Erin B. Bailey
No relevant relationships to disclose
Srinivas Kiran Tantravahi
No relevant relationships to disclose
Austin Poole
No relevant relationships to disclose
Chesley E. Wells
No relevant relationships to disclose
Julia A. Batten
No relevant relationships to disclose
Joseph Merriman
No relevant relationships to disclose
David D. Stenehjem
No relevant relationships to disclose
Neeraj Agarwal
No relevant relationships to disclose